This study will evaluate the efficacy and safety of the study drug in treating type 2
diabetes in children 10 to 17 years old.
The groups will be low-dose (0.625 g Welchol) and high-dose (3.75 g Welchol). The children
will have a 2 in 5 chance of being assigned to the low-dose group. They will have a 3 in 5
chance of being assigned to the high-dose group.
We believe the study drug will be safe, well tolerated, and improve blood sugar control in
children 10 to 17 years old.